Parabolan 76.5mg/ml 10ml Vial by Magnus Pharmaceuticals

Usage

1. Confirm lot-specific HPLC documentation for your Magnus Parabolan vial before the first injection — batch records link the vial's lot number to measured concentration data.
2. Warm the sealed vial to room temperature (approximately 20–22 °C) for 5–10 minutes to reduce oil viscosity and ensure smooth passage through the injection needle.
3. Draw the required volume (1.0 ml for a 76.5 mg dose) using a 21-gauge drawing needle; switch to a clean 25-gauge, 1-inch needle for the intramuscular injection itself to minimise tissue trauma.
4. Inject into a large muscle group — the gluteus medius or ventrogluteal site is preferred for oil-based depots — using a slow, steady plunger depression over 20–30 seconds to distribute the oil evenly.
5. Rotate injection sites systematically across each administration to prevent depot accumulation, scar tissue formation, and localised inflammation at any single site.
6. Record injection date, volume, and site in a training log; cross-reference against bloodwork dates so that ALT, AST, haematocrit, and lipid panels are drawn at meaningful intervals relative to active plasma levels — not arbitrarily.

Warnings

Frequently asked questions

Why does the injectable form of Trenbolone Hexahydrobenzylcarbonate have higher bioavailability than any oral trenbolone compound?

Injectable Trenbolone Hexahydrobenzylcarbonate achieves close to 100% systemic bioavailability because the intramuscular depot releases free Trenbolone directly into capillaries, completely bypassing hepatic first-pass metabolism. An oral trenbolone dose, by contrast, would travel via the portal vein to the liver, where CYP3A4-mediated oxidation would destroy a large fraction of the active molecule before it could reach muscle tissue.

What is first-pass metabolism and how does it reduce the effectiveness of oral androgens compared to injectable ones?

First-pass metabolism is the hepatic biotransformation of a drug that occurs between gut absorption and systemic circulation. Portal blood delivers gut-absorbed molecules to liver hepatocytes, where phase-I enzymes oxidise, hydroxylate, or conjugate them — reducing circulating drug concentrations by 60–90% for high-extraction-ratio androgens. Injectable androgens deposit into muscle and drain into systemic venous blood, skipping the portal circuit entirely and preserving the full administered dose.

How does the rate of Trenbolone absorption differ between an intramuscular oil depot and a theoretical oral tablet?

From an intramuscular oil depot, esterases in interstitial fluid cleave the hexahydrobenzylcarbonate group at a rate determined by ester lipophilicity and depot surface area, producing a sustained release of free Trenbolone detectable by LC-MS/MS over multiple days. A theoretical oral tablet would depend on gastrointestinal dissolution, epithelial transport, and hepatic survival — three sequential filtration steps that collectively and unpredictably reduce the dose fraction reaching systemic circulation.

Can Magnus Pharmaceuticals Parabolan 76.5mg/ml be drawn with an insulin syringe, and what volume corresponds to a 76.5 mg dose?

Yes — the 76.5 mg/ml concentration means a 1.0 ml draw equals exactly one full dose of 76.5 mg, which is manageable with a 1 ml luer-lock syringe. For precise sub-dose increments, a 1 ml insulin-type syringe calibrated in 0.1 ml graduations delivers 7.65 mg per mark. Always use a separate 21–23 gauge drawing needle and switch to a 25 gauge injection needle for the actual intramuscular administration.

How should the Magnus Parabolan 10ml vial be stored after first use, and what is the recommended shelf life once opened?

After first puncture, store the vial upright at 15–25 °C away from direct light and moisture; refrigeration is not required but the vial should not be exposed to temperature extremes that cause the oil carrier to crystallise. The multi-dose rubber stopper is rated for repeated sterile access when a fresh needle is used for every draw. Most manufacturers recommend using an opened vial within 28 days; inspect visually for particulates or colour change before each use. (2) angle_used

Manufacturer

Magnus Pharmaceuticals' production capacity is architectured around a dedicated multi-line fill facility in which injectable oil-based products — Parabolan among them — are manufactured on equipment validated specifically for sterile, non-aqueous pharmaceutical fill operations. Facility throughput is organised by dosage form rather than by compound category: the injectable line processes different active ingredients sequentially under strictly segregated change-over protocols, with equipment contact surfaces cleaned, rinsed, and re-validated between each API campaign to prevent cross-contamination at the microgram level. Capacity planning at Magnus incorporates projected demand forecasting across the full injectable portfolio, enabling production batch sizes to be scaled in a way that preserves fill-date freshness — a logistically significant advantage for end users who receive vials within a shelf-life window that reflects recent manufacture rather than extended warehouse holding. The fill environment itself operates under ISO Class 5 laminar-flow conditions for all open-container steps, with continuous particle monitoring during each production campaign providing real-time data that is logged against the batch record. Quality-control throughput on the injectable line is dimensioned to match fill output: every batch of Parabolan produced by Magnus Pharmaceuticals advances to HPLC potency quantification and LAL bacterial endotoxin testing before a release decision is issued, ensuring that production capacity and analytical capacity remain aligned rather than creating release bottlenecks that could incentivise premature dispatch.